Pila Pharma AB (publ) (PILA.ST)
SEK 3.06
(-4.53%)
SEK 3.06
(-4.53%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 7.85 Million SEK | -90.0% |
| 2022 | 10.77 Million SEK | 8.34% |
| 2021 | 9.94 Million SEK | 244.36% |
| 2020 | 2.88 Million SEK | 9.51% |
| 2019 | 2.63 Million SEK | 30.54% |
| 2018 | 2.01 Million SEK | -57.8% |
| 2017 | 4.78 Million SEK | 339.43% |
| 2016 | 1.08 Million SEK | 355.09% |
| 2015 | 239.28 Thousand SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 579 Thousand SEK | 0.0% |
| 2024 Q1 | 579 Thousand SEK | 114.44% |
| 2023 Q2 | 2.05 Million SEK | -22.05% |
| 2023 Q4 | 270 Thousand SEK | -82.21% |
| 2023 Q1 | 2.64 Million SEK | 109.21% |
| 2023 Q3 | 1.51 Million SEK | -26.24% |
| 2023 FY | 1.07 Million SEK | -90.0% |
| 2022 Q4 | -28.65 Million SEK | -1216.35% |
| 2022 Q2 | 2.9 Million SEK | 7.96% |
| 2022 FY | 10.77 Million SEK | 8.34% |
| 2022 Q1 | 2.68 Million SEK | -29.08% |
| 2022 Q3 | 2.56 Million SEK | -11.51% |
| 2021 Q1 | 2.43 Million SEK | 50.31% |
| 2021 FY | 9.94 Million SEK | 244.36% |
| 2021 Q4 | 3.78 Million SEK | 19.36% |
| 2021 Q3 | 3.17 Million SEK | 99.0% |
| 2021 Q2 | 1.59 Million SEK | -34.5% |
| 2020 Q3 | 294 Thousand SEK | 0.0% |
| 2020 FY | 2.88 Million SEK | 9.51% |
| 2020 Q4 | 1.61 Million SEK | 451.02% |
| 2019 FY | 2.63 Million SEK | 30.54% |
| 2018 FY | 2.01 Million SEK | -57.8% |
| 2017 FY | 4.78 Million SEK | 339.43% |
| 2016 FY | 1.08 Million SEK | 355.09% |
| 2015 FY | 239.28 Thousand SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 99.481% |
| AcouSort AB (publ) | 25.87 Million SEK | 69.639% |
| Active Biotech AB (publ) | 44.8 Million SEK | 82.467% |
| Alzinova AB (publ) | 36.39 Million SEK | 78.414% |
| Amniotics AB (publ) | 29.07 Million SEK | 72.977% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | 46.385% |
| BioArctic AB (publ) | 89.62 Million SEK | 91.234% |
| Camurus AB (publ) | 1.05 Billion SEK | 99.259% |
| Cantargia AB (publ) | 290.01 Million SEK | 97.291% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | 64.118% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | 72.265% |
| Genovis AB (publ.) | 88.19 Million SEK | 91.092% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 93.173% |
| Mendus AB (publ) | 129.13 Million SEK | 93.916% |
| Kancera AB (publ) | 63.07 Million SEK | 87.545% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -42.35% |
| LIDDS AB (publ) | 27.75 Million SEK | 71.691% |
| Lipum AB (publ) | 37.3 Million SEK | 78.942% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -8.303% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 94.22% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | 52.099% |
| NextCell Pharma AB | -576.01 Thousand SEK | 1463.891% |
| OncoZenge AB (publ) | 15.9 Million SEK | 50.605% |
| Saniona AB (publ) | 1.07 Million SEK | -629.459% |
| Simris Alg AB (publ) | 38.64 Million SEK | 79.669% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 97.556% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 97.803% |
| Xintela AB (publ) | 57.31 Million SEK | 86.293% |
| Ziccum AB (publ) | 27.87 Million SEK | 71.819% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -8.094% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 95.677% |
| CombiGene AB (publ) | 44.14 Million SEK | 82.203% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 94.506% |
| Intervacc AB (publ) | 79.78 Million SEK | 90.153% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 97.442% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | 81.572% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | 55.572% |
| Corline Biomedical AB | 30.16 Million SEK | 73.958% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 86.462% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 90.554% |
| Aptahem AB (publ) | 10.01 Million SEK | 21.539% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 94.167% |
| Fluicell AB (publ) | 28.61 Million SEK | 72.547% |
| Biovica International AB (publ) | 133.72 Million SEK | 94.125% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | 60.302% |
| Abliva AB (publ) | 27.86 Million SEK | 71.807% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 95.94% |
| 2cureX AB (publ) | 36.51 Million SEK | 78.487% |
| I-Tech AB | 40.14 Million SEK | 80.432% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 99.086% |
| Cyxone AB (publ) | 28.21 Million SEK | 72.155% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 92.817% |
| Biosergen AB | 26.8 Million SEK | 70.695% |
| Nanologica AB (publ) | 69.88 Million SEK | 88.759% |
| SynAct Pharma AB | 224.49 Million SEK | 96.5% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | 82.216% |
| BioInvent International AB (publ) | 441.4 Million SEK | 98.22% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | 67.203% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 97.289% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 92.917% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | 46.556% |